Show simple item record

dc.contributor.authorLamarca, Angela
dc.contributor.authorEdeline, J
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorHubner, Richard A
dc.contributor.authorNagino, M
dc.contributor.authorBridgewater, J
dc.contributor.authorPrimrose, J
dc.contributor.authorValle, Juan W
dc.date.accessioned2020-02-27T16:55:26Z
dc.date.available2020-02-27T16:55:26Z
dc.date.issued2020en
dc.identifier.citationLamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.en
dc.identifier.pmid31986437en
dc.identifier.doi10.1016/j.ctrv.2019.101936en
dc.identifier.urihttp://hdl.handle.net/10541/622769
dc.description.abstractBiliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60-70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies. Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community. This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ctrv.2019.101936en
dc.titleCurrent standards and future perspectives in adjuvant treatment for biliary tract cancersen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalCancer Treatment Reviewsen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record